Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice~* Be female and ≥18 and ≤75 years of age~* Be ambulatory and have ECOG performance stastus of ≤1~* Have histological confirmed breast cancer,and the speciman confirmed ER negative,PR negatiev, and HER-2 negative by immunochemistry technich of Fudan cancer hospital.~* Locally advanced or metastastic breast cancer who didn't receive first-line chemotherapy. No matter whether the patient has received anthracyclin or taxane treatment as neo-adjuvant or adjuvant treatment.~* Have at least one target lesion according to the RECIST criteria.~Exclusion criteria:~* Preganant or lactating women~* Advaced patient has received one or more chemotherapies~* Chemotherapy within four weeks preceding treatment start~* ECOG ≥ 2~* Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy~* Participation in any investigational drug study within 4 weeks preceeding treatment start~* Evidence of CNS metastasis~* History of another malignacy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer~* Abnormal laboratory values: hemoglobin \< 8. 0g/dl, neutrophil\< 1.5×109/L, platelet\< 100×109/L.~* serum creatine \> upper limit of normal (ULN)~* serum bilirubin \> ULN~* ALT and AST \>5×ULN~* AKP \>5×ULN~* Serious uncontrolled intercurrence infection~* Life expectancy of less than 3 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- gemcitabine and cisplatin (Type: EXPERIMENTAL): cisplatin and gemcitabine in the management of triple negative metastatic breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).